WO2004052347A1 - Medicaments pour administration par voie transmuqueuse ou transdermique a resorption de principes actifs amelioree - Google Patents

Medicaments pour administration par voie transmuqueuse ou transdermique a resorption de principes actifs amelioree Download PDF

Info

Publication number
WO2004052347A1
WO2004052347A1 PCT/EP2003/013537 EP0313537W WO2004052347A1 WO 2004052347 A1 WO2004052347 A1 WO 2004052347A1 EP 0313537 W EP0313537 W EP 0313537W WO 2004052347 A1 WO2004052347 A1 WO 2004052347A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoterpenes
medicament according
group
substances
transmucosal
Prior art date
Application number
PCT/EP2003/013537
Other languages
German (de)
English (en)
Inventor
Christian Von Falkenhausen
Markus Krumme
Tina Rademacher
Original Assignee
Lts Lohmann Therapie-Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie-Systeme Ag filed Critical Lts Lohmann Therapie-Systeme Ag
Priority to AU2003289929A priority Critical patent/AU2003289929A1/en
Publication of WO2004052347A1 publication Critical patent/WO2004052347A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on

Definitions

  • the present invention relates to medicaments for transmucosal or transdermal administration of active substances, these medicaments containing a combination of auxiliaries which improve or accelerate the transmucosal or transdermal absorption of active substances (“enhancers”).
  • the invention further comprises the use of such medicaments for the administration of active substances, and also preparations for the production of transmucosal or transdermal dosage forms, these preparations having a content of absorption-improving additives.
  • transmucosal administration of active substances in particular the administration via the oral mucosa (e.g. by means of buccal dosage forms), is extremely advantageous from a galenical point of view, because it results in a quick onset of action and a higher bioavailability. So far, sprays or sublingual tablets have mainly been used for this type of administration.
  • Film-like systems which can be administered orally have become known as a novel dosage form for oral transmucosal or transbuccal administration.
  • These film-shaped systems can be equipped with mucoadhesive properties, so that they remain on the mucous membrane, e.g. B. on the buccal (or gingival) mucosa, can adhere.
  • the film-shaped systems can - by suitable selection of the formulation constituents - be designed as films which are decomposable, partially decomposable or non-decomposable in aqueous media.
  • the active ingredient contained in the system is released to the environment released and partially transmucosal resorbed, but partially swallowed with saliva.
  • the swallowed portion of the amount of active substance released is therefore not available for transmucosal absorption, which reduces the bioavailability of the active substance.
  • transdermal therapeutic systems which are intended to enable the controlled administration of pharmaceutical drugs over a longer period of time, usually over several hours or days. Since the skin is a barrier for many active substances, it is crucial with transdermal drugs to improve the absorption of active substances through the skin.
  • the object of the present invention was therefore to show substances or mixtures of substances which improve the transmucosal and transdermal absorption of active substances (so-called “enhancers”), and also medicaments which are distinguished by improved transdermal or transmucosal absorption of active substances.
  • medicaments for transmucosal or transdermal administration which contain at least one substance from the group of monterpenes and at the same time at least one substance from the group of polyalcohols.
  • the addition of such a combination of substances improves the absorption of the active substance through the oral mucosa.
  • the addition of the combination of enhancers mentioned brings about an improvement in the transdermal absorption of the active substance.
  • the combination according to the invention of at least one substance from the group of Monoterpenes and at least one substance from the group of the polyalcohols thus acts as an enhancer with regard to the transmucosal as well as the transdermal absorption of the active substance.
  • the enhancer effect could be due to the fact that the monoterpenes act as vasodilators for accelerated removal of the active substance, whereas the polyalcohols which are also present serve as plasticizers.
  • Aliphatic monoterpenes such as. B. Myrcen, Oci en
  • Cyclic monoterpenes such as. B. alpha-pinene, camphene, i-monene, phellandrene, pinene, sabine, terpinene;
  • Monoterpenes with a carbonyl group such as. B. Campher, Carvon, Citral, Cuminaldehyde, Dihydrocarvon, Fenchon, Safranal, Thujon;
  • phenolic monoterpenes such as. B. anethole, carvacrol, eugenol, eucalyptol, methylcavicol, thymol, trans-anethole;
  • Phenylpropane such as.
  • Polyhydric alcohols such as glycol, propanediol, butanediol etc. can preferably be used as polyalcohols, furthermore trihydric or polyhydric alcohols, in particular glycerol.
  • polyvinyl alcohols are particularly suitable. These can also act as matrix formers, ie as a component that is involved in the formation of the solid matrix of the drug.
  • the enhancer mixture contained in the medicament contains a combination of two or more substances from the group of monoterpenes or / and a combination of two or more substances from the group of polyalcohols.
  • the enhancer mixture contains at least one substance from the group of the monoterpenes and at least one substance from the group of the polyalcohols.
  • Menthol or a mixture of other monoterpenes containing menthol is preferably used as an enhancer mixture in combination with at least one polyalcohol selected from the group comprising propanediol, butanediol and glycerol.
  • transmucosal or transdermal medicaments additionally contain dex-panthenol and / or one or more salts of pantothenic acid.
  • the enhancer substances are preferably present in the pharmaceutical formulation in the proportions mentioned below (based on the dry matter): monoterpenes: 0.5 to 40% by weight, preferably 3 to 30% by weight, particularly preferably 5 to 20 wt .-%; Polyalcohols: 0.5 to 80% by weight, preferably 3 to 30% by weight, particularly preferably 5 to 20% by weight;
  • the pharmaceuticals according to the invention preferably have an essentially solid matrix; this may contain one or more matrix-forming substances, at least one active substance and the substances mentioned which improve the absorption of the active substance.
  • the medicaments for transmucosal active ingredient delivery which contain the enhancer mixtures according to the invention, are preferably formulated as film-like pharmaceutical forms.
  • suitable matrix formers and auxiliaries these can be endowed with mucoadhesive properties; however, the invention also encompasses non-mucoadhesive film-shaped drugs.
  • the invention further extends to mucoadhesive or non-mucoadhesive film-shaped medicaments which are soluble or / and disintegrable in aqueous media or physiological liquids.
  • Suitable matrix formers and auxiliary substances are known to the person skilled in the art.
  • the films can be formulated as either fast or slow release systems.
  • transmucosal drugs can also be formulated as dosage forms which are insoluble or non-disintegrating in aqueous media.
  • aqueous media means in particular physiological liquids, in particular saliva.
  • transmucosal, in particular film-shaped drugs according to the invention are preferably formulated as oral dosage forms; in addition, the invention also includes medicaments which are intended for vaginal or rectal administration.
  • matrix-forming substances which are suitable for forming the solid or semi-solid matrix (basic structure) of a medicament.
  • This matrix generally represents the reservoir for the active substance (s) to be administered.
  • the proportion by weight of the matrix-forming constituents is preferably in the range from 10 to 95% by weight, particularly preferably in the range from 15 to 70% by weight. %, in each case based on the entire drug (dry matter).
  • Particularly suitable matrix-forming polymers are: polyvinyl alcohol (PVA), polyethylene oxides, copolymers of methyl vinyl ether and maleic acid, cellulose derivatives such as hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), sodium carboxymethyl cellulose (NaCMC), methyl cellulose (MC) , Hydroxyethyl cellulose (HEC), hydroxypropyl ethyl cellulose (HPEC), polysaccharides, starch and their derivatives, gelatins, polyvinylpyrrolidones (PVP), gum arabic, pullulan or acrylates. Mixtures of two or more of the polymers mentioned can also be used. Substances from the following groups can advantageously be used as auxiliary substances which are known in principle to the person skilled in the art: fillers such as SiC>2; Dyes like
  • Emulsifiers such as Tween (polyethoxylated sorbitan fatty acid esters), Brij (polyethoxylated fatty alcohols); Sweeteners such as aspartame, sodium cyclate and saccharin; Plasticizers such as PEG (polyethylene glycol) or glycerin; Preservatives such as sorbic acid or its salts; Antioxidants.
  • the proportion of these auxiliaries can preferably be up to 30% by weight, in particular 1 to 20% by weight, in each case based on the entire medicament (dry matter).
  • the active substance content is generally 0.5 to 50% by weight, preferably 1 to 40% by weight, particularly preferably 5 to 30% by weight, in each case based on the entire medicament (dry matter).
  • the total thickness of a transmucosal, in particular a film-like drug can be 5 ⁇ m to 5 mm, preferably 30 ⁇ m to 2 mm and particularly preferably 50 ⁇ m to 1 mm.
  • the surface shape can advantageously be round, oval, triangular or quadrangular, polygonal or have any shape that is rounded. Such dosage forms are often referred to as "afer”.
  • the medicinal products according to the invention for transmucosal administration are generally produced in such a way that a coating composition is first prepared using water, alcohol or other solvents and contains the active substance (s), matrix-forming constituents and optionally auxiliary substances. This coating composition is coated onto an inert base by doctor blade, roller application, spraying or extrusion processes and dries, forming a film layer. This is then divided into surface sections of a suitable size.
  • the present invention further relates to medicaments for the transdermal administration of active substances, in particular transdermal therapeutic systems (TTS) such as, for. B. transdermal patches.
  • TTS transdermal therapeutic systems
  • the structure of such systems, the matrix-forming substances and auxiliaries suitable for this, and also production processes suitable for this are known in principle to the person skilled in the art.
  • the transdermal medicaments according to the invention are preferably designed as pressure-sensitive adhesive systems on the skin.
  • the typical structure of a TTS comprises a backing layer which is impermeable to active substances and auxiliary substances (for example plastic film, such as PETP, PE), an associated active substance-containing reservoir and a removable protective layer (for example PE or PETP film, siliconized) or fluorosiliconized), which covers the skin contact side of the active substance reservoir during storage or before application.
  • auxiliary substances for example plastic film, such as PETP, PE
  • PETP PETP film, siliconized
  • fluorosiliconized for example PE or PETP film, siliconized
  • Polymers from the following groups are particularly suitable as polymers for producing the active substance reservoir: polyacrylates, poly (meth) acrylates, polyacrylic acid, cellulose derivatives, in particular methyl and ethyl celluloses, isobutylene,
  • Ethylene vinyl acetate natural and synthetic rubbers such as styrene-diene copolymers, styrene-butadiene block copolymers, isoprene block copolymers, acrylonitrile-butadiene rubber, butyl rubber or neoprene rubber, silicone pressure sensitive adhesive and hot-melt adhesive. Suitable mixtures of the polymers mentioned can also advantageously be used.
  • the polymer matrix of the active substance reservoir can be constructed in one or more layers. The proportion of these polymers can preferably be 10 to 90% by weight, preferably 20 to 70% by weight, in each case based on the total weight of a TTS in the dried state.
  • the active substance reservoir of the TTS according to the invention can also contain various auxiliaries or additives, for example from the group of solubilizers, solvents, plasticizers, tackifiers, pH regulators, antioxidants and preservatives; Suitable substances are known to the person skilled in the art.
  • the active substance content in the reservoir is preferably in the range from 0.1 to 50% by weight, particularly preferably in the range from 5 to 30% by weight, in each case based on the total weight of a TTS in the dried state.
  • the procedure can be such that active ingredient (s), matrix-forming polymers and, if appropriate, auxiliary (s) are dissolved or suspended in a suitable solvent or solvent mixture and the resulting coating composition is placed on a suitable base, for example one with a Plastic film provided with silicone layer, is coated. After the solvent components have been dried and evaporated, the active substance-containing matrix layer is covered with a further film, which represents the later back layer of the TTS.
  • individual TTS are made from such a laminate.
  • active substances which can be administered transdermally or transmucosally by means of the medicaments according to the invention, in principle all compounds or mixtures of substances which are therapeutically or prophylactically active in humans or animals are suitable.
  • agents for infection treatment antivirals
  • Analgesics such as feritanyl, buprenorphine, anesthetics
  • Anorectika Drugs for the treatment of arthritis and asthma, such as terbutaline; anticonvulsants; Antidepressants; antidiabetics; antihistamines; antidiarrheals; Anti-migraine drugs; Anti-nausea and nausea drugs, Travel or seasickness, such as B.
  • scopolamine and ondansetron antineoplastic agents; Anti-Parkinson agents; Antipsychotics; Antpyretika; antispasmodics; anticholinergics; Anti-ulcer agents such as ranitidine; sympathomimetic; Calcium channel blockers such as nifedipine; Beta-blockers; Beta-agonists; Antiarrhythmics; Antihypertensives such as atenolol; ACE inhibitors such as enalapril; Benzodiazepine agonists such as flumazenil; coronary, peripheral and cerebral vasodilators; substances acting on the central nervous system; hormones; hypnotics; Immunosuppressants; muscle relaxants; prostaglandins; Proteins, peptides; Psychostimulants; Sedatives, tranquilizers.
  • Suitable active substances can also be found in the active substance groups of the parasympatholytics (e.g. scopolamine, atropine), the parasympathomimetics, the cholinergics (e.g. physostigmine, nicotine), the neuroleptics (e.g. chlorpromazine, haloperidol), the Monoamine oxidase inhibitors, the sympathomimetics (e.g. ephedrine, D-norpseudoephedrine, salbutamol, fenfluramine), the sympatholytics and antisympathotonics (e.g.
  • the parasympatholytics e.g. scopolamine, atropine
  • the parasympathomimetics e.g. physostigmine, nicotine
  • the neuroleptics e.g. chlorpromazine, haloperidol
  • the Monoamine oxidase inhibitors e.g
  • propranolol, timolol, bupranolol, clonidine, dihydroergotamine) (the anx. B. diazepam, triazolam), local anesthetics (e.g. lidocaine), central anaesthetics (e.g. fentanyl, sufentanil), antirheumatic drugs (e.g. indomethacin, piroxicam, lornoxicam), coronary drugs (e.g.
  • the invention further extends to preparations which can be used for the production of transmucosal or transdermal dosage forms, the preparations containing at least one matrix former and at least one pharmaceutical active ingredient.
  • these preparations additionally contain at least one substance from the group of the monoterpenes and at least one substance from the group of the polyalcohols, as indicated above.
  • the medicaments according to the invention can advantageously be used for the transdermal or transmucosal, in particular oral, vaginal or rectal administration of active substance (s) for the treatment or prophylaxis of diseases in humans or animals.
  • FIG. 1 shows the in vivo application of the enhancer system according to the invention (upper curve or upper bar) in comparison with a reference system (lower curve or lower bar).
  • upper curve or upper bar the enhancer system according to the invention
  • lower curve or lower bar the reference system

Abstract

L'invention concerne des médicaments pour l'administration de principes actifs par voie transmuqueuse ou transdermique, lesquels médicaments sont caractérisés en ce qu'ils contiennent au moins une substance du groupe des monoterpènes et au moins une substance du groupe des polyalcools pour une meilleure résorption des principes actifs.
PCT/EP2003/013537 2002-12-05 2003-12-02 Medicaments pour administration par voie transmuqueuse ou transdermique a resorption de principes actifs amelioree WO2004052347A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003289929A AU2003289929A1 (en) 2002-12-05 2003-12-02 Transmucosal and transdermal medicaments with an improved active ingredient absorption

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10256774.3 2002-12-05
DE2002156774 DE10256774A1 (de) 2002-12-05 2002-12-05 Transmucosale und transdermale Arzneimittel mit verbesserter Wirkstoffresorption

Publications (1)

Publication Number Publication Date
WO2004052347A1 true WO2004052347A1 (fr) 2004-06-24

Family

ID=32335982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/013537 WO2004052347A1 (fr) 2002-12-05 2003-12-02 Medicaments pour administration par voie transmuqueuse ou transdermique a resorption de principes actifs amelioree

Country Status (5)

Country Link
AR (1) AR042308A1 (fr)
AU (1) AU2003289929A1 (fr)
DE (1) DE10256774A1 (fr)
TW (1) TW200427464A (fr)
WO (1) WO2004052347A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006048501A1 (fr) * 2004-11-05 2006-05-11 Orion Corporation Préparation vétérinaire transmuqueuse comprenant de la détomidine
EP1676559A2 (fr) * 2005-01-03 2006-07-05 L'oreal Article cosmétique ou dermatologique comportant un support soluble dans l'eau
US8309120B2 (en) 2005-10-21 2012-11-13 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for administering lipophilic and/or sparingly skin- permeable active substances
US20140056949A1 (en) * 2010-11-15 2014-02-27 The Regents Of The University Of Michigan Controlled Release Mucoadhesive Systems
WO2018129313A1 (fr) * 2017-01-06 2018-07-12 Clexio Biosciences Ltd. Formulations topiques de détomidine
US11185532B2 (en) 2019-05-01 2021-11-30 Clexio Biosciences Ltd. Methods of treating pruritus

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006027794A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antihypertonie-Kombinationswafer
DE202008017304U1 (de) 2008-02-29 2009-08-27 Acino Ag Oral zerfallender Film zur therapeutischen Anwendung von Antiparasitika bei Tieren

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0480054A1 (fr) * 1990-03-30 1992-04-15 Morimoto, Yasunori Composition absorbable par voie percutanee du chlorhydrate de morphine
WO1993021899A1 (fr) * 1992-05-05 1993-11-11 The Procter & Gamble Company Composition de traitement de l'acne
WO1994006436A1 (fr) * 1992-09-12 1994-03-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Emplatre contenant du dexpanthenol pour application transcutanee d'hormones steroides
DE19620341A1 (de) * 1996-05-21 1997-11-27 Erich Dr Med Dr Phil Both Geriatrin (Medikament gegen Altersbeschwerden in percutaner Einreibung)
WO1999016434A1 (fr) * 1997-09-26 1999-04-08 Sam Yang Co., Ltd. Systeme d'administration transdermique de medicament pour agent analgesique et anti-inflammatoire comportant du sel de diclofenac-diethylammonium et procede de fabrication correspondant
WO2002034294A1 (fr) * 2000-10-27 2002-05-02 Bionorica Ag Utilisation de terpenes en tant qu'amplificateurs de la resorption transmuqueuse, et preparations pharmaceutiques contenant des terpenes
WO2002066016A2 (fr) * 2001-02-19 2002-08-29 Lts Lohmann Therapie-Systeme Ag Preparation medicinale mucoadhesive degradable pour l'administration de principes actifs en medecine humaine et veterinaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053384A1 (de) * 2000-10-27 2002-05-08 Bionorica Arzneimittel Gmbh Pharmazeutische Zubereitung aus Mariendistel und Terpenen
DE10100811A1 (de) * 2001-01-10 2002-07-18 Walther Schoenenberger Pflanze Verwendung von ätherischen Ölen zur topischen Behandlung oder Prophylaxe von Wundheilungsstörungen
DE10118282A1 (de) * 2001-04-12 2002-12-05 Lohmann Therapie Syst Lts Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke
DE10121471A1 (de) * 2001-05-02 2002-11-07 Beiersdorf Ag Oberflächendotierte wirkstoffhaltige Pflaster

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0480054A1 (fr) * 1990-03-30 1992-04-15 Morimoto, Yasunori Composition absorbable par voie percutanee du chlorhydrate de morphine
WO1993021899A1 (fr) * 1992-05-05 1993-11-11 The Procter & Gamble Company Composition de traitement de l'acne
WO1994006436A1 (fr) * 1992-09-12 1994-03-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Emplatre contenant du dexpanthenol pour application transcutanee d'hormones steroides
DE19620341A1 (de) * 1996-05-21 1997-11-27 Erich Dr Med Dr Phil Both Geriatrin (Medikament gegen Altersbeschwerden in percutaner Einreibung)
WO1999016434A1 (fr) * 1997-09-26 1999-04-08 Sam Yang Co., Ltd. Systeme d'administration transdermique de medicament pour agent analgesique et anti-inflammatoire comportant du sel de diclofenac-diethylammonium et procede de fabrication correspondant
WO2002034294A1 (fr) * 2000-10-27 2002-05-02 Bionorica Ag Utilisation de terpenes en tant qu'amplificateurs de la resorption transmuqueuse, et preparations pharmaceutiques contenant des terpenes
WO2002066016A2 (fr) * 2001-02-19 2002-08-29 Lts Lohmann Therapie-Systeme Ag Preparation medicinale mucoadhesive degradable pour l'administration de principes actifs en medecine humaine et veterinaire

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO338158B1 (no) * 2004-11-05 2016-08-01 Orion Corp En transmukosal veterinærsammensetning som omfatter detomidin
JP2008519012A (ja) * 2004-11-05 2008-06-05 オリオン コーポレーション デトミジンを含む経粘膜動物用組成物
US7863311B2 (en) 2004-11-05 2011-01-04 Orion Corporation Transmucosal veterinary composition comprising detomidine
AU2005300451B2 (en) * 2004-11-05 2011-01-20 Orion Corporation A transmucosal veterinary composition comprising detomidine
US8309591B2 (en) 2004-11-05 2012-11-13 Orion Corporation Transmucosal veterinary composition comprising detomidine
WO2006048501A1 (fr) * 2004-11-05 2006-05-11 Orion Corporation Préparation vétérinaire transmuqueuse comprenant de la détomidine
EP1676559A2 (fr) * 2005-01-03 2006-07-05 L'oreal Article cosmétique ou dermatologique comportant un support soluble dans l'eau
FR2880262A1 (fr) * 2005-01-03 2006-07-07 Oreal Article cosmetique ou dermatologique comportant un support soluble dans l'eau
EP1676559A3 (fr) * 2005-01-03 2006-09-13 L'oreal Article cosmétique ou dermatologique comportant un support soluble dans l'eau
US8309120B2 (en) 2005-10-21 2012-11-13 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for administering lipophilic and/or sparingly skin- permeable active substances
US9486417B2 (en) 2005-10-21 2016-11-08 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for administering lipophilic and/or sparingly skin-permeable active substances
US20140056949A1 (en) * 2010-11-15 2014-02-27 The Regents Of The University Of Michigan Controlled Release Mucoadhesive Systems
US10758619B2 (en) * 2010-11-15 2020-09-01 The Ohio State University Controlled release mucoadhesive systems
US11679157B2 (en) 2010-11-15 2023-06-20 The Ohio State University Controlled release mucoadhesive systems
WO2018129313A1 (fr) * 2017-01-06 2018-07-12 Clexio Biosciences Ltd. Formulations topiques de détomidine
JP2020505322A (ja) * 2017-01-06 2020-02-20 クレキシオ バイオサイエンシーズ エルティーディー． 局所用デトミジン製剤
AU2018205217B2 (en) * 2017-01-06 2023-11-09 Clexio Biosciences Ltd. Topical detomidine formulations
US11185532B2 (en) 2019-05-01 2021-11-30 Clexio Biosciences Ltd. Methods of treating pruritus
US11903928B2 (en) 2019-05-01 2024-02-20 Clexio Biosciences Ltd. Methods of treating pruritus

Also Published As

Publication number Publication date
AU2003289929A1 (en) 2004-06-30
DE10256774A1 (de) 2004-06-24
AR042308A1 (es) 2005-06-15
TW200427464A (en) 2004-12-16

Similar Documents

Publication Publication Date Title
DE69923675T2 (de) Pharmazeutische trägervorrichtung welche zur verabreichung von wirkstoffen an schleimhautoberflächen geeignet ist
US6375963B1 (en) Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
EP2252272B1 (fr) Plaquette gingivale
US20060257463A1 (en) Transmucosal delivery of cannabinoids
AU2018200402A1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
DE202006018608U1 (de) Buprenorphin-Wafer zur Drogensubstitutionstherapie
EP2273987B1 (fr) Préparation en forme de film comprenant des substances huileuses et destinée à l'administration orale
DE10224607B4 (de) Filmförmige, zerfallsfähige Zubereitungen zur Wirkstofffreisetzung und Verfahren zu deren Herstellung
NO325073B1 (no) Preparat for anvendelse i munnhulen med en film eller sjikt som viser oyeblikkelig fuktbarhet.
JP2007502823A (ja) 接着性および生体侵食性の経粘膜薬物送達システム
EP1850836B1 (fr) Traitement medicamenteux combine
DE102019135432A1 (de) Lösliche Rückschicht für OTF
EP1638521A1 (fr) Forme d'administration trans-muqueuse a irritation reduite des muqueuses
EP1971328A1 (fr) Système thérapeutique percutané pour des substances volatiles et/ou thermolabiles
WO2004052347A1 (fr) Medicaments pour administration par voie transmuqueuse ou transdermique a resorption de principes actifs amelioree
JP2006316009A (ja) 口腔内貼付剤及びその製造方法
EP2889030A1 (fr) Contrôler les taux d'érosion de dispositifs muco-adhésifs qui fournissent des actifs et d'autres composés et fournir des niveaux sanguins thérapeutiques variables et accrus
EP1761242A2 (fr) Agent pharmaceutique a administration orale, en forme de film, contenant de l'oestriol
Shinde et al. Recent updates on oral and dermal film-based formulations and their applications
DE102021100779A1 (de) Mehrschichtiger oraler dünnfilm
DE102021100780A1 (de) Oraler dünnfilm mit pva-tris-pufferschicht
DE102021120937A1 (de) Oraler Dünnfilm
DE102021106491A1 (de) Gerollte oral thin films mit hoher wirkstoffbeladung
EP3995137A1 (fr) Film mince orale
DE102021130950A1 (de) Applikationshilfe

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN IL IN JP KR MX NZ PH PL RU US ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP